Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007
In: Measuring and Modeling Health Care Costs
Author
Abstract
(This abstract was borrowed from another version of this item.)
Suggested Citation
Download full text from publisher
Other versions of this item:
- Rena M. Conti & Ernst R. Berndt, 2014. "Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007," NBER Working Papers 20016, National Bureau of Economic Research, Inc.
References listed on IDEAS
- Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013.
"The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity,"
NBER Chapters, in: Measuring and Modeling Health Care Costs, pages 243-271,
National Bureau of Economic Research, Inc.
- Murray L. Aitken & Ernst R. Berndt & Barry Bosworth & Iain M. Cockburn & Richard Frank & Michael Kleinrock & Bradley T. Shapiro, 2013. "The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity," NBER Working Papers 19487, National Bureau of Economic Research, Inc.
- Gaynor, Martin & Vogt, William B, 2003.
"Competition among Hospitals,"
RAND Journal of Economics, The RAND Corporation, vol. 34(4), pages 764-785, Winter.
- Martin Gaynor & William Vogt, 2002. "Competition Among Hospitals," GSIA Working Papers 2003-E20, Carnegie Mellon University, Tepper School of Business.
- Martin Gaynor & William B. Vogt, 2003. "Competition Among Hospitals," NBER Working Papers 9471, National Bureau of Economic Research, Inc.
- Martin Gaynor & William B Vogt, 2003. "Competition among Hospitals," The Centre for Market and Public Organisation 03/087, The Centre for Market and Public Organisation, University of Bristol, UK.
- Richard G. Frank & David S. Salkever, 1997.
"Generic Entry and the Pricing of Pharmaceuticals,"
Journal of Economics & Management Strategy, Wiley Blackwell, vol. 6(1), pages 75-90, March.
- Richard G. Frank & David S. Salkever, 1995. "Generic Entry and the Pricing of Pharmaceuticals," NBER Working Papers 5306, National Bureau of Economic Research, Inc.
- Griliches, Zvi & Cockburn, Iain, 1994.
"Generics and New Goods in Pharmaceutical Price Indexes,"
American Economic Review, American Economic Association, vol. 84(5), pages 1213-1232, December.
- Griliches, Z. & Cockborn, I., 1993. "Generics and New Goods in Pharmaceutical Price Indexes," Harvard Institute of Economic Research Working Papers 1664, Harvard - Institute of Economic Research.
- Zvi Griliches & Iain Cockburn, 1993. "Generics and New Goods in Pharmaceutical Price Indexes," NBER Working Papers 4272, National Bureau of Economic Research, Inc.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Liang Xu & Vidya Mani & Hui Zhao, 2023. "“Not a box of nuts and bolts”: Distribution channels for specialty drugs," Production and Operations Management, Production and Operations Management Society, vol. 32(7), pages 2283-2303, July.
- R. Brett McQueen & Kelly E. Anderson & Joseph F. Levy & Josh J. Carlson, 2023. "Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?," PharmacoEconomics, Springer, vol. 41(3), pages 321-327, March.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Claudia Allende & Juan Pablo Atal & Rodrigo Carril & Jose Ignacio Cuesta & Andrés González Lira, 2023.
"Drivers of public procurement prices: Evidence from pharmaceutical markets,"
Economics Working Papers
1874, Department of Economics and Business, Universitat Pompeu Fabra.
- Claudia Allende & Juan Pablo Atal & Rodrigo Carril & José Ignacio Cuesta & Andres Gonzalez-Lira, 2023. "Drivers of Public Procurement Prices: Evidence from Pharmaceutical Markets," Working Papers 1413, Barcelona School of Economics.
- Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011.
"Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008,"
CESifo Working Paper Series
3441, CESifo.
- Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
- Joan-Ramon Borrell & Jayashree Watal, 2002. "Impact of Patents on Access to HIV/AIDS Drugs in Developing Countries," CID Working Papers 92, Center for International Development at Harvard University.
- Thiago Caliari & Roberto Mazzoleni & Luciano Martins Costa Póvoa, 2013. "Innovation in the pharmaceutical industry in Brazil post-TRIPS," Chapters, in: Sunil Mani & Richard R. Nelson (ed.), TRIPS Compliance, National Patent Regimes and Innovation, chapter 2, pages 16-56, Edward Elgar Publishing.
- Regan, Tracy L., 2008.
"Generic entry, price competition, and market segmentation in the prescription drug market,"
International Journal of Industrial Organization, Elsevier, vol. 26(4), pages 930-948, July.
- Tracy L. Regan, 2007. "Generic entry, price competition, and market segmentation in the prescription drug market," Working Papers 2010-7, University of Miami, Department of Economics.
- Ferrara, Ida & Missios, Paul, 2012.
"Pricing of drugs with heterogeneous health insurance coverage,"
Journal of Health Economics, Elsevier, vol. 31(2), pages 440-456.
- Paul Missios & Ida Ferrara, 2010. "Pricing of Drugs with Heterogeneous Health Insurance Coverage," Working Papers 026, Toronto Metropolitan University, Department of Economics.
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016.
"Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,"
RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- Ying Kong, 2004. "The price premium of generic to brand-names and pharmaceutical price index," Applied Economics, Taylor & Francis Journals, vol. 36(7), pages 731-737.
- Stéphane Jacobzonne & Edouard Martin & Vincent Perrin & Julien Werle, 1997. "Une approche hedonique de la formation des prix des médicaments remboursables," Économie et Prévision, Programme National Persée, vol. 129(3), pages 73-99.
- Costa-Font, Joan & McGuire, Alistair & Varol, Nebibe, 2014. "Price regulation and relative delays in generic drug adoption," Journal of Health Economics, Elsevier, vol. 38(C), pages 1-9.
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2024.
"The Economics of the Public Option: Evidence from Local Pharmaceutical Markets,"
American Economic Review, American Economic Association, vol. 114(3), pages 615-644, March.
- Juan Pablo Atala & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2021. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Documentos de Trabajo 561, Instituto de Economia. Pontificia Universidad Católica de Chile..
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2023. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Working Papers 951, Queen Mary University of London, School of Economics and Finance.
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2022. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," NBER Working Papers 30779, National Bureau of Economic Research, Inc.
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2021. "The Economics of the Public Option:Evidence from Local Pharmaceutical Markets," PIER Working Paper Archive 21-012, Penn Institute for Economic Research, Department of Economics, University of Pennsylvania.
- Merja Halme & Kari Linden & Kimmo Kääriä, 2009. "Patients’ Preferences for Generic and Branded Over-the-Counter Medicines," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 2(4), pages 243-255, December.
- Pan, Jay & Qin, Xuezheng & Li, Qian & Messina, Joseph P. & Delamater, Paul L., 2015. "Does hospital competition improve health care delivery in China?," China Economic Review, Elsevier, vol. 33(C), pages 179-199.
- Susan J. Méndez & Jongsay Yong & Hugh Gravelle & Anthony Scott, 2024. "Medical pricing decisions: Evidence from Australian specialists," Melbourne Institute Working Paper Series wp2024n11, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
- Eduardo Pontual Ribeiro & Victor Gomes, 2016. "Retail Entry Effects On Pharmaceuticals Prices: A View From Large Retail Chains In Brazil," Anais do XLIII Encontro Nacional de Economia [Proceedings of the 43rd Brazilian Economics Meeting] 139, ANPEC - Associação Nacional dos Centros de Pós-Graduação em Economia [Brazilian Association of Graduate Programs in Economics].
- Martin Gaynor, "undated".
"What Do We Know About Competition and Quality in Health Care Markets?,"
GSIA Working Papers
2006-E62, Carnegie Mellon University, Tepper School of Business.
- Martin Gaynor, 2006. "What Do We know About Competition and Quality in Health Care Markets?," The Centre for Market and Public Organisation 06/151, The Centre for Market and Public Organisation, University of Bristol, UK.
- Martin Gaynor, 2006. "What Do We Know About Competition and Quality in Health Care Markets?," NBER Working Papers 12301, National Bureau of Economic Research, Inc.
- Lakdawalla, Darius & Sood, Neeraj, 2013.
"Health insurance as a two-part pricing contract,"
Journal of Public Economics, Elsevier, vol. 102(C), pages 1-12.
- Darius Lakdawalla & Neeraj Sood, 2006. "Health Insurance as a Two-Part Pricing Contract," NBER Working Papers 12681, National Bureau of Economic Research, Inc.
- Berndt Ernst R. & Cockburn Iain M. & Cocks Douglas L. & Epstein Arnold M. & Griliches Zvi, 1998.
"Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs,"
Forum for Health Economics & Policy, De Gruyter, vol. 1(1), pages 1-45, January.
- Ernst R. Berndt & Iain M. Cockburn & Douglas L. Cocks & Arnold M. Epstein & Zvi Griliches, 1998. "Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs," NBER Chapters, in: Frontiers in Health Policy Research, Volume 1, pages 33-76, National Bureau of Economic Research, Inc.
- Ernst R. Berndt & Iain M. Cockburn & Douglas L. Cocks & Arnold Epstein & Zvi Griliches, 1997. "Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs," NBER Working Papers 6182, National Bureau of Economic Research, Inc.
- Bate, Roger & Jin, Ginger Zhe & Mathur, Aparna, 2011.
"Does price reveal poor-quality drugs? Evidence from 17 countries,"
Journal of Health Economics, Elsevier, vol. 30(6), pages 1150-1163.
- Roger Bate & Ginger Zhe Jin & Aparna Mathur, 2011. "Does Price Reveal Poor-Quality Drugs? Evidence from 17 Countries," NBER Working Papers 16854, National Bureau of Economic Research, Inc.
- Robert Town & Douglas Wholey & Roger Feldman & Lawton R. Burns, 2006. "The Welfare Consequences of Hospital Mergers," NBER Working Papers 12244, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- D04 - Microeconomics - - General - - - Microeconomic Policy: Formulation; Implementation; Evaluation
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- L11 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Production, Pricing, and Market Structure; Size Distribution of Firms
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberch:13100. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.